Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Biosciences (Nasdaq: SNTI) participated in a Virtual Investor CEO Connect segment on Jan 14, 2026, where CEO Timothy Lu discussed two regulatory milestones and new clinical data. The U.S. FDA granted RMAT designation to SENTI-202, a potential first-in-class logic gated off-the-shelf CAR-NK investigational therapy for relapsed/refractory hematologic malignancies including AML, building on an Orphan Drug designation awarded in June. Dr. Lu also reviewed data from 20 patients (18 with evaluable responses) in the ongoing multinational SENTI-202 trial, with results presented at the American Society of Hematology (ASH) Annual Meeting.
Senti Biosciences (Nasdaq: SNTI) announced that Dr. Timothy Lu, co-founder and CEO, will serve as a panelist at Biotech Showcase 2026 in San Francisco, taking place January 12–14, 2026. The panel, titled "Engineering the Future: Advances in Cell and Gene Therapies", is scheduled for Tuesday, January 13, 2026 at 8:00 AM PST in Workshop 1 (Yosemite A).
The session features industry leaders from pharmaphorum, Diakonos Oncology, Opus Genetics, IN8bio, and Epicrispr Biotechnologies and will discuss advances in cell and gene therapies using technologies such as gene circuits. Investors can view session details on the conference website.
Senti Biosciences (Nasdaq: SNTI) announced that on Dec 12, 2025 its board granted inducement stock options to one new employee to purchase 13,680 shares at an exercise price of $1.31 per share. The awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan and were described as material inducements under Nasdaq Listing Rule 5635(c)(4). The Plan was initially adopted by the board on Aug 5, 2022. No additional financial guidance, vesting schedule, or dilutive impact was disclosed in the announcement.
Senti Bio (Nasdaq: SNTI) announced the FDA has granted RMAT designation to SENTI-202 on December 9, 2025 for adults with relapsed or refractory acute myeloid leukemia (R/R AML).
Designation follows an Orphan Drug designation in June 2025 and is supported by Phase 1 data presented at ASH on December 8, 2025 showing 50% ORR, 42% CR/CRh at the RP2D and a 7.6-month median duration of composite complete remission; data also show selective killing of leukemic cells while sparing healthy progenitors.
Senti Biosciences (Nasdaq: SNTI) reported updated SENTI-202 Phase 1 data in 20 relapsed/refractory AML patients (18 evaluable) presented at ASH 2025 on Dec 9, 2025. Key results at the RP2D: 50% ORR, 42% CR/CRh; overall: 50% ORR, 39% CR/CRh. 100% of CRs and ~80% of responses were MRD negative. Median duration of composite complete remissions across all patients was 7.6 months (KM estimate). SENTI-202 showed pharmacodynamic validation of its OR/NOT Logic Gate targeting, a favorable safety profile with no DLTs or SENTI-202-related SAEs, and received FDA RMAT designation.
Senti Bio (Nasdaq: SNTI) will host a conference call and webcast on Tuesday, December 9, 2025 at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting.
Presenters include Timothy Lu, MD, PhD (CEO, co‑founder), Kanya Rajangam, MD, PhD (President, Head of R&D, CMO) and external investigator Nosha Farhadfar, MD from Sarah Cannon Transplant & Cellular Therapy Program. Investors can join by phone or via webcast on the company Investors Events page; the webcast will be archived for 90 days after the live event.
Senti Biosciences (Nasdaq: SNTI) reported third-quarter 2025 results and confirmed a clinical data readout for the Phase 1 SENTI-202 study in acute myeloid leukemia at the American Society of Hematology (ASH) Annual Meeting on December 6-9, 2025.
Key figures: cash and cash equivalents $12.2M as of September 30, 2025 (vs. $48.3M at year-end 2024), R&D $10.5M, G&A $6.4M, and net loss $18.1M or $0.69 per share for Q3 2025. Company will present updated SENTI-202 clinical and correlative data and host a webcast during ASH.
Senti Bio (Nasdaq: SNTI) will present updated clinical results for SENTI-202, a first‑in‑class CD33/FLT3 & not EMCN logic‑gated off‑the‑shelf CAR NK cell therapy, at the ASH Annual Meeting, Dec 6–9, 2025.
The company announced two presentations on Dec 8, including an oral session (abs25-10130) at 5:45–6:00 PM and a poster (abs25-2711) at 6:00–8:00 PM. Reported highlights include deep, durable clinical remissions, a strong safety profile, and pharmacodynamic data showing selective killing of leukemic blasts and leukemic stem cells while sparing healthy hematopoietic stem and progenitor cells. A live webcast will accompany the ASH presentations.
Senti Biosciences (Nasdaq: SNTI) announced that CEO and co‑founder Timothy Lu, MD, PhD will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 in New York.
The live webcast of the presentation will be available on the company’s Investors > Events page and management will be available for one‑on‑one investor meetings for registered attendees.
Senti Biosciences (Nasdaq: SNTI) will present in person at BioJapan October 8-10, 2025. The presentation by Timothy Lu, MD, PhD, CEO and co-founder, is scheduled for Thursday, October 9 at 11:30 AM JST on Presentation Stage C at PACIFICO Yokohama Convention Center in Yokohama, Japan.
Management will be available for one-on-one investor meetings with qualified registered attendees and will host an exhibition booth at D-53. For participation details, refer to the conference website.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
